Primary ADT ineffective for most men with early stage prostate cancer

Data from a large, retrospective study, reported in the Journal of Clinical Oncology, suggest something that many expert clinicians and patients have long suspected … that early use of androgen deprivation therapy (ADT) alone is not an effective treatment for most men with early stage prostate cancer. … READ MORE …

Supervised exercise and prevention of ADT-related side effects

A small, randomized trial in a group of 60+ Australian patients has demonstrated that a supervised exercise program started at the same time as initiation of androgen deprivation therapy (ADT) can have multiple beneficial results, including (at least temporary) avoidance of known side effects of ADT. … READ MORE …

AR gene amplification and risk for CRPC

An article just published in the British Journal of Cancer, has proposed that androgen receptor (AR) gene amplification may be a prime cause of treatment failure in a subset of men with progressive prostate cancer. … READ MORE …

Does normal expression of SPOP prevent development of many prostate cancers?

Researchers from the Mayo Clinic in Rochester, MN, are claiming that they have made a series of four important discoveries related to the role of a protein called “speckle-type POZ protein” (SPOP) and its involvement in the development of prostate cancer. … READ MORE …

The androgen receptor pathway … this morning in San Francisco

So today’s early morning session of the GU Oncology meeting was highly focused on the evolution of newer therapies affecting the androgen receptor pathways in the treatment of advanced and progressive forms of prostate cancer. … READ MORE …

Quality of life in the first 2 years on ADT for non-metastatic patients

A forthcoming paper in the Journal of Urology has attempted to quantify the effects of androgen deprivation therapy (ADT) on the mental and emotional well-being of men with non-metastatic prostate cancer. … READ MORE …

Baseline serum androgen levels and responses to abiraterone acetate

Baseline levels of serum androgens were predictive for clinical response to treatment in the Phase III clinical trial of abiraterone acetate in men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC), according to a new article in the Journal of Clinical Oncology. … READ MORE …

Prevention of bone-related and metabolic complications of treatment for men on ADT

A new article from an Australian clinical research group in the journal Andrology addresses “the effectiveness of implementing standardized guidelines to mitigate metabolic and bone side effects of androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer.” … READ MORE …

Radiation therapy, neoadjuvant ADT, and initial PSA response

New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer. … READ MORE …

Australian researchers identify “castration-tolerant cancer-repopulating cells” in mouse model

According to a media release issued earlier today in Australia, “a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments.” … READ MORE …

Sipuleucel-T before or after ADT in men with biochemically recurrent disease?

A paper to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is entitled, “A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results.” … READ MORE …

Expert opinion on ADT for CRPC today

As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used to. … READ MORE …

Abiraterone acetate for men with metastatic disease and a sub-optimal response to ADT

The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …

New meta-analysis endorses IADT for good responders to initial CADT

A new meta-analysis of data from nine large clinical trials suggests that, “There is fair evidence to recommend use of [intermittent] instead of [continuous androgen deprivation] for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation.” … READ MORE …

Over-use of neoadjuvant and concurrent ADT in combination with radiation therapy

As anyone who has had long-term androgen deprivation therapy is well aware, this type of treatment may be able to delay the onset or relieve the metastases and bone pain associated with progressive prostate cancer, but it is far from being benign — and comes with a wide spectrum of side effects that affect some patients very seriously. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers